Life Scientist > Biotechnology

Cannabis-based epilepsy drug coming in 2018

07 December, 2017

MGC Pharmaceuticals has executed a binding definitive exclusive supply agreement with pharmaceutical wholesaler HL Pharma to bring its adult epilepsy product, CannEpil, to the Australian market in 2018.


Bio-Gene Technology collaborates with CSIRO on insecticide development

01 December, 2017

Bio-Gene Technology, a manufacturer of insecticides, has entered into an extended research agreement with CSIRO to develop improved manufacturing systems for its lead product, Flavocide.


Strong anticancer activity identified in newly patented AAD compounds

29 November, 2017

PharmAust has been granted a new patent in the US covering its portfolio of anticancer drugs, recently proven to be more effective at killing cancer cells than their parent compound.


Lonza XS Pichia 2.0 Expression and Manufacturing Platform

24 November, 2017

Lonza has developed an expression and manufacturing system that provides high product titres (up to 6 g/L) along with a fast, robust and scalable manufacturing process suitable for commercial production. The XS Pichia 2.0 system is said to deliver high cell viability for improved product quality; reduced fermentation times that approximate E. coli processes; and ease of implementation in large-scale plants.


Biotron compounds demonstrate antiviral activity against hep B

17 November, 2017

Biotron has announced that several of its compounds have demonstrated significant antiviral activity against hepatitis B (HBV) in recently completed preclinical studies.


Prima BioMed announces positive data, pre-IND meeting for anticancer candidate

16 November, 2017

Prima BioMed has presented new data from a phase I clinical trial investigating eftilagimod alpha, its anticancer candidate, in combination with pembrolizumab in unresectable or metastatic melanoma patients.


Shining a light on small diseased tissues

13 November, 2017

Singaporean researchers have created polymer nanoagents that can 'light up' tiny areas of diseased tissues that conventional methods fail to detect.


New ARC training centre dedicated to biopharmaceuticals

09 November, 2017

The ARC Industrial Transformation Training Centre in Biopharmaceutical Innovation has been officially opened at The University of Queensland, 16 months after it was initially announced.


Researchers discover a missing piece of the drug design jigsaw

10 October, 2017

UK researchers have discovered a new way of analysing how drugs interact with molecules in the body, which could lead to the development of better treatments with fewer side effects.


MTPConnect signs MoU with Medical Alley Association

05 October, 2017

MTPConnect has signed a memorandum of understanding with the Medical Alley Association, a Minnesota-based organisation that enables health innovation and care organisations to successfully influence the evolution of health care.


Printed medication: the future of pharmaceuticals

03 October, 2017

US scientists have developed technology that can print pure, ultraprecise doses of drugs onto a wide variety of surfaces, in a breakthrough that could one day enable on-site printing of custom-dosed medications at pharmacies, hospitals and other locations.


Diabetes drug found to have anti-ageing properties

18 September, 2017

Australian researchers have discovered that metformin, a common anti-diabetic drug, could have anti-ageing properties which could lead to longer, healthier lifespans.


BioScience Managers invests in REX Bionics

12 September, 2017

Australian life sciences investment firm BioScience Managers has chosen a robotic exercise assist device (REX) as its first investment for the Biomedical Translation Fund.


2017 Medical Devices Fund winners announced

11 September, 2017

The NSW Government announced the winners of the Medical Devices Fund at a ceremony held at Parliament House.


Medtech entrepreneur Lusia Guthrie joins BioMelbourne Network board

08 September, 2017

BioMelbourne Network has announced the appointment of Lusia Guthrie to its board of directors. With over 35 years in pharmaceutical and bioscience industries, Guthrie is an experienced executive and medtech entrepreneur, with strong leadership skills and international industry networks.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd